C-Rad AB (STO:CRADB), a developer of innovative solutions for use in advanced radiation therapy, reported on Friday net result after tax of SEK24.3m, or SEK0.79 per share, for the fourth quarter of 2018.

This was an increase over net result after tax of SEK0.8m, or SEK0.03 per share, in fourth quarter 2017.

Order intake for the quarter was SEK75.6m, up by 59% as compared with SEK47.5m in the previous fourth quarter.

Revenues for the quarter were SEK57.7m, up by 37% as compared with SEK42.0m in the same period of the year before.

According to C-Rad, significant growth in order intake across all segments during the quarter led to record order intake in the company's history. At the same time, revenue and profit both grew healthy in its fourth quarter and helped to close 2018 with a profit, a first for the company.

C-Rad offers products and solutions for patient positioning, tumour localisation and radiation treatment systems. All product development is conducted in the three fully owned subsidiaries of C-Rad Positioning AB, C-Rad Imaging AB and C-Rad Innovation AB.

(EUR1.00=SEK10.5)